preparation and characterization of lpd nanoparticles containing rgp63 and rlmacin as a vaccine against cutaneous leishmaniasis

Liposomes containing the imiquimod adjuvant as a vaccine in the cutaneous leishmaniasis model

Objective(s): Attempts to produce vaccines for leishmaniasis need adjuvants to trigger the kind of immune reaction required for protection. In this study, we examined the properties of the TLR7 agonist imiquimod, a vaccine adjuvant, making use of a live model of infection where the immune reactions could be identified prior to and following the challenge of infection. Materials and Method...

evaluation of the efficacy of lpd-nanoparticles containing rgp63 in the induction of cmi and protection against cl in murine model of leishmaniasis

synthesis and characterization of some new cyclometalated organoplatinum(ii) complexes containing phosphite ligand

در این تحقیق روشی جهت سنتز یک سری از کمپلکس های پلاتین (ii) حاوی لیگاند های دهنده ی فسفری شامل فسفیت و فسفین ارائه شده است. واکنش پیش ماده ی پلاتین (ii)،trans/cis- [ptcl2(sme2)2] ، با 2 اکی مولار از لیگاند p(oph)3در حلال بنزن کمپلکس1، cis-[ptcl2(p(oph)3)2] را تولید می نماید. جهت سنتز کمپلکس سایکلو متال فسفیتی، کمپلکس 1 با 1 اکی والان واکنشگر ptcl2 در حلال زایلن در شرایط رفلاکس زیر گاز آرگون م...

Preparation and characterization of PLGA Nanoparticles containing recombinant core-NS3 Fusion protein of hepatitis C virus as a nano-vaccine candidate

Introduction: Hepatitis C virus (HCV) is one of the most serious causes of cirrhosis, liver cancer and ultimately death, worldwide. The new direct-acting drugs are not accessible for many patients around the world and progress toward new therapeutic and anaphylactic vaccines design has not been fast enough. This study was aimed to prepare and assess a recombinant fusion protein core-NS3 (rC-N) ...

Comparative evaluation of phenol and thimerosal as preservatives for a candidate vaccine against American cutaneous leishmaniasis.

For decades thimerosal has been used as a preservative in the candidate vaccine for cutaneous leishmaniasis, which was developed by Mayrink et al. The use of thimerosal in humans has been banned due to its mercury content. This study addresses the standardization of phenol as a new candidate vaccine preservative. We have found that the proteolytic activity was abolished when the test was conduc...

TRIAL OF A NON-LIVING CRUDE VACCINE AGAINST ZOONOTIC CUTANEOUS LEISHMANIASIS

A field trial was canied outon60 volunteers selected in Yazd province, central Iran, with a vaccine containing killed promastigotes of L. major prepared by the Razi Institute, Hessarak. During these phase I studies which lasted for more than two years, we examined acceptable doses of the vaccine alone or mixed with BCG. The results so far indicate that 50 to 1000 µg of the vaccine alone can...